Boardroom Alpha
Boardroom Alpha
TCX · Current Report (Form 8-K) · Filed June 4, 2026

Tucows Inc — Current Report (Form 8-K)

Form
8-K
Filed
June 4, 2026
Period
Jun 2, 2026
Ticker
TCX
Accession
0001437749-26-019571
Boardroom Alpha · Filing insights

Shareholders elected the listed directors for one-year terms, approved non-binding executive compensation, and ratified Deloitte as auditors.

About Tucows Inc
Market cap
$101M
1Y TSR
−38.3%
3Y TSR
−19.8%
Board grade
C
Sector
Technology
CEO
Elliot Noss
Last annual meeting: Jun 2, 2026 · View full Tucows Inc profile →
tcx20260604_8k.htm
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 

 
FORM 8-K
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported): June 2, 2026
 
 
TUCOWS INC
(Exact Name of Registrant Specified in Charter)
 
Pennsylvania
0-28284
23-2707366
(State or Other
(Commission File
(IRS Employer
Jurisdiction of
Number)
Identification No.)
Incorporation)
   
 
96 Mowat Avenue, Toronto, Ontario, Canada
 
M6K 3M1
(Address of Principal Executive Offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code: (416) 535-0123
 
Not Applicable
 
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
Securities registered pursuant to Section 12(b) of the Exchange Act:
 
Title of each class
 
Trading Symbol(s)
 
Name of each exchange on which registered
Common Stock
 
TCX
 
NASDAQ
 
 
 

 
 
Item 5.07.               Submission of Matters to a Vote of Security Holders.
 
Tucows Inc. (the “Company”) held its Annual Meeting of Shareholders (the “Annual Meeting”) on June 2, 2026. The following matters, all of which were set forth in the Company’s definitive proxy statement on Schedule 14A (the “Proxy Statement”) filed with the Securities and Exchange Commission on April 23, 2026, were voted on at the Annual Meeting. The results of such voting are as indicated below.
 
Proposal 1. Election of Directors
 
The Company’s shareholders voted upon and elected the following nominees to serve on the Company’s Board of Directors for a term of one year expiring at the 2027 Annual Meeting of Shareholders.
 
Nominee for Director
 
Votes For
 
Authority Withheld
Marlene Carl
 
6,777,982
 
627,741
Lee Matheson
 
6,705,717
 
700,006
Sandra Matz
 
7,331,744
 
73,979
Laurenz Malte Nienaber
 
6,243,490
 
1,162,233
Allen Taylor
 
6,830,376
 
575,347
Jeffrey Tory
 
7,369,190
 
36,533
Stephen Uhrenbacher
 
6,764,168
 
641,555
David Woroch
 
6,831,227
 
574,496
 
There were 668,178 broker non-votes with respect to the election of directors.
 
Proposal 2. Non-binding Advisory vote on the Compensation of Named Executive Officers
 
The Company’s shareholders voted upon and approved, on a non-binding basis, the compensation of the Company’s named Executive Officers as disclosed in the Proxy Statement.
 
For
 
Against
 
Abstain
 
6,778,876
 
624,527
 
2,320
 
 
 
There were 668,178 broker non-votes with respect to the Non-binding advisory vote on Named Executive Officer Compensation
 
Proposal 3. Ratification of Appointment of Independent Auditors
 
The Company’s shareholders voted upon and ratified the appointment of Deloitte LLP as the independent auditors of the Company and its subsidiaries for the fiscal year ending December 31, 2026.
 
For
 
Against
 
Abstain
 
8,046,168
 
2,080
 
25,653
 
 
 
 

 
 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
TUCOWS INC.
 
       
 
By:
/s/ Ivan Ivanov
 
   
Ivan Ivanov
Chief Financial Officer
 
Dated: June 4, 2026
 
 
 
 
From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Tucows Inc (TCX)

Reference

Frequently asked questions

When did Tucows Inc file this 8-K?
Tucows Inc (TCX) filed this Current Report (Form 8-K) with the SEC on June 4, 2026. The accession number assigned by EDGAR is 0001437749-26-019571.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Shareholders elected the listed directors for one-year terms, approved non-binding executive compensation, and ratified Deloitte as auditors. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Tucows Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Tucows Inc has filed under CIK 909494, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer